MedTrace Logo

Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis

NCT07796516 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2026-09-01

No results posted yet for this study

Summary

This study is a multicenter, open-label, randomized controlled trial designed to preliminarily evaluate the efficacy and safety of telitacicept in patients with refractory rheumatoid arthritis during a 24-week treatment period followed by a 2-week follow-up period.

Conditions

Interventions

BIOLOGICAL

Telitacicept 160mg

Telitacicept 160 mg will be administered subcutaneously once weekly for 24 consecutive weeks.

DRUG

Standard therapy

Standard therapy includes DMARDs, GCs, and NSAIDs.

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2027-12-30
Completion
2028-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07796516 on ClinicalTrials.gov